# Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients

> **NCT00128232** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 100 (—)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** Octreotide LAR

## Key facts

- **NCT ID:** NCT00128232
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2004-08
- **Final completion:** —
- **Target enrollment:** 100 (—)
- **Last updated:** 2012-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00128232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00128232, "Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00128232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*